Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Depreciation & Amortization (2016 - 2025)

Iovance Biotherapeutics has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $48.8 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $48.8 million for Q4 2025, up 35.4% from a year ago — trailing twelve months through Dec 2025 was $48.8 million (up 35.4% YoY), and the annual figure for FY2025 was $48.8 million, up 35.4%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $48.8 million at Iovance Biotherapeutics, up from $45.3 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for IOVA hit a ceiling of $48.8 million in Q4 2025 and a floor of $19.4 million in Q1 2023.
  • Median Accumulated Depreciation & Amortization over the past 3 years was $33.5 million (2024), compared with a mean of $33.7 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 59.45% in 2024 and later grew 25.48% in 2025.
  • Iovance Biotherapeutics' Accumulated Depreciation & Amortization stood at $27.9 million in 2023, then increased by 29.04% to $36.0 million in 2024, then surged by 35.4% to $48.8 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $48.8 million (Q4 2025), $45.3 million (Q3 2025), and $42.1 million (Q2 2025) per Business Quant data.